165 related articles for article (PubMed ID: 25468225)
21. Glioblastoma.
Wirsching HG; Galanis E; Weller M
Handb Clin Neurol; 2016; 134():381-97. PubMed ID: 26948367
[TBL] [Abstract][Full Text] [Related]
22. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
23. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Arvold ND; Tanguturi SK; Aizer AA; Wen PY; Reardon DA; Lee EQ; Nayak L; Christianson LW; Horvath MC; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Alexander BM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):384-9. PubMed ID: 25841623
[TBL] [Abstract][Full Text] [Related]
24. Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy.
Dincoglan F; Beyzadeoglu M; Sager O; Demiral S; Gamsiz H; Uysal B; Ebruli C; Akin M; Oysul K; Sirin S; Dirican B
Tumori; 2015; 101(2):179-84. PubMed ID: 25791534
[TBL] [Abstract][Full Text] [Related]
25. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.
Lee P; Murphy B; Miller R; Menon V; Banik NL; Giglio P; Lindhorst SM; Varma AK; Vandergrift WA; Patel SJ; Das A
Anticancer Res; 2015 Feb; 35(2):615-25. PubMed ID: 25667438
[TBL] [Abstract][Full Text] [Related]
27. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
29. Gliomas and the vascular fragility of the blood brain barrier.
Dubois LG; Campanati L; Righy C; D'Andrea-Meira I; Spohr TC; Porto-Carreiro I; Pereira CM; Balça-Silva J; Kahn SA; DosSantos MF; Oliveira Mde A; Ximenes-da-Silva A; Lopes MC; Faveret E; Gasparetto EL; Moura-Neto V
Front Cell Neurosci; 2014; 8():418. PubMed ID: 25565956
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
31. Treatment of anaplastic glioma.
Wick W; Wiestler B; Platten M
Cancer Treat Res; 2015; 163():89-101. PubMed ID: 25468227
[TBL] [Abstract][Full Text] [Related]
32. Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Azoulay M; Santos F; Souhami L; Panet-Raymond V; Petrecca K; Owen S; Guiot MC; Patyka M; Sabri S; Shenouda G; Abdulkarim B
Radiat Oncol; 2015 Apr; 10():106. PubMed ID: 25927334
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Wong ET; Lok E; Swanson KD
Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708
[TBL] [Abstract][Full Text] [Related]
34. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
35. Proton therapy for low-grade gliomas: Results from a prospective trial.
Shih HA; Sherman JC; Nachtigall LB; Colvin MK; Fullerton BC; Daartz J; Winrich BK; Batchelor TT; Thornton LT; Mancuso SM; Saums MK; Oh KS; Curry WT; Loeffler JS; Yeap BY
Cancer; 2015 May; 121(10):1712-9. PubMed ID: 25585890
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
Castro BA; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E9. PubMed ID: 25581938
[TBL] [Abstract][Full Text] [Related]
38. Survival outcomes in elderly patients with glioblastoma.
Tsang DS; Khan L; Perry JR; Soliman H; Sahgal A; Keith JL; Mainprize TG; Das S; Zhang L; Tsao MN
Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):176-83. PubMed ID: 25549930
[TBL] [Abstract][Full Text] [Related]
39. Current opinion on bevacizumab on endometrial cancer treatment.
Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
Expert Opin Biol Ther; 2015 Feb; 15(2):299-307. PubMed ID: 25539414
[TBL] [Abstract][Full Text] [Related]
40. Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment.
Ding SS; Li L; Yu CX
J BUON; 2014; 19(4):965-72. PubMed ID: 25536603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
